middle.news
How Syntara’s Amsulostat Could Redefine Myelofibrosis Treatment
8:46am on Tuesday 28th of October, 2025 AEDT
•
Healthcare
Read Story
How Syntara’s Amsulostat Could Redefine Myelofibrosis Treatment
8:46am on Tuesday 28th of October, 2025 AEDT
Key Points
73% of patients achieved ≥50% symptom improvement at 6 months+
44% of patients showed ≥25% spleen volume reduction with durable effects
No treatment-related serious adverse events reported up to 12 months
FDA feedback clarifies clinical development pathway for amsulostat
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE